Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 112 participants.
Also called NCT03186404
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 112 participants
- Sponsor
- Registry
-
NCT03186404
-
- Other papers using this trial's data
- Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Unknown status
Technical summary
Registry record NCT03186404. Randomized; quadruple masking; primary purpose prevention. Start 2018-05-10 (actual); primary completion 2021-12-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study
- Acronym
- SPARE-HF
- Condition
- Cancer
- Condition
- Heart Failure
- Condition
- Cardiotoxicity
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Placebo oral tablet
- Lead sponsor
- University Health Network, Toronto
- Collaborator
- Mount Sinai Hospital, Canada
- Collaborator
- Unity Health Toronto
- Collaborator
- Sunnybrook Health Sciences Centre
- Collaborator
- Scarborough General Hospital
Record details
- Record id
cardio:ct-nct03186404- Content hash
36a3db0254fbe96c64722c0a63e41021915905fa0f7630b21a7398af872f9afc